|
Gene: SDR42E1 |
Gene summary for SDR42E1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SDR42E1 | Gene ID | 93517 |
Gene name | short chain dehydrogenase/reductase family 42E, member 1 | |
Gene Alias | HSPC105 | |
Cytomap | 16q23.3 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8WUS8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
93517 | SDR42E1 | C04 | Human | Oral cavity | OSCC | 9.61e-11 | 5.96e-01 | 0.2633 |
93517 | SDR42E1 | C21 | Human | Oral cavity | OSCC | 1.11e-19 | 5.27e-01 | 0.2678 |
93517 | SDR42E1 | C30 | Human | Oral cavity | OSCC | 7.32e-12 | 5.66e-01 | 0.3055 |
93517 | SDR42E1 | C43 | Human | Oral cavity | OSCC | 8.53e-03 | 1.10e-01 | 0.1704 |
93517 | SDR42E1 | C46 | Human | Oral cavity | OSCC | 5.74e-08 | 2.06e-01 | 0.1673 |
93517 | SDR42E1 | C57 | Human | Oral cavity | OSCC | 1.27e-02 | 1.65e-01 | 0.1679 |
93517 | SDR42E1 | C08 | Human | Oral cavity | OSCC | 2.61e-06 | 1.56e-01 | 0.1919 |
93517 | SDR42E1 | LN46 | Human | Oral cavity | OSCC | 1.24e-05 | 2.35e-01 | 0.1666 |
93517 | SDR42E1 | SYSMH2 | Human | Oral cavity | OSCC | 2.38e-02 | 1.46e-01 | 0.2326 |
93517 | SDR42E1 | SYSMH3 | Human | Oral cavity | OSCC | 8.79e-12 | 3.28e-01 | 0.2442 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
GO:00082024 | Oral cavity | OSCC | steroid metabolic process | 146/7305 | 319/18723 | 7.78e-03 | 2.85e-02 | 146 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SDR42E1 | SNV | Missense_Mutation | novel | c.193G>C | p.Glu65Gln | p.E65Q | Q8WUS8 | protein_coding | tolerated(0.27) | benign(0.221) | TCGA-98-A53B-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SDR42E1 | deletion | In_Frame_Del | novel | c.333_335delNNN | p.Arg114del | p.R114del | Q8WUS8 | protein_coding | TCGA-85-A53L-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
SDR42E1 | SNV | Missense_Mutation | novel | c.719G>A | p.Arg240Lys | p.R240K | Q8WUS8 | protein_coding | tolerated(0.52) | benign(0.001) | TCGA-BA-A6DJ-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
SDR42E1 | SNV | Missense_Mutation | novel | c.592N>A | p.Pro198Thr | p.P198T | Q8WUS8 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-CV-7411-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SDR42E1 | SNV | Missense_Mutation | novel | c.667N>A | p.Val223Ile | p.V223I | Q8WUS8 | protein_coding | tolerated(0.08) | benign(0.401) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
SDR42E1 | SNV | Missense_Mutation | c.500N>G | p.Asn167Ser | p.N167S | Q8WUS8 | protein_coding | tolerated(0.07) | benign(0.122) | TCGA-BR-8362-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD | |
SDR42E1 | SNV | Missense_Mutation | c.629N>C | p.Lys210Thr | p.K210T | Q8WUS8 | protein_coding | tolerated(0.44) | benign(0.043) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SDR42E1 | SNV | Missense_Mutation | rs370136905 | c.842N>A | p.Arg281His | p.R281H | Q8WUS8 | protein_coding | tolerated(0.2) | benign(0.023) | TCGA-HU-A4GC-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
SDR42E1 | SNV | Missense_Mutation | rs200329125 | c.190N>A | p.Val64Ile | p.V64I | Q8WUS8 | protein_coding | tolerated(0.28) | benign(0.044) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
SDR42E1 | insertion | Frame_Shift_Ins | novel | c.9dupC | p.Lys4GlnfsTer36 | p.K4Qfs*36 | Q8WUS8 | protein_coding | TCGA-BR-8591-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |